|  |
| --- |
| Table 1: Demographic and Clinical Characteristics of Study Cohort |
|  | **Total****(n=2288)** |  **No thrombo-prophylaxis** **(n=1538)** | **Thrombo-****prophylaxis (n=750)** | **p value** |
| **Age, years** | 71.7 (6.9) | 71.7 (6.9) | 71.8 (6.8) | 0.68 |
| **Body mass index, kg/m2** | 28.4 (4.7) | 28.2 (4.7) | 28.7 (4.6) | **0.01** |
| **Parity** | 2 (2-3) | 2 (2-3) | 2 (2-3) | **0.02** |
| **Current smoker** | 75 (3.4) | 47 (3.2) | 28 (3.8) | 0.44 |
| **Hispanic ethnicity** | 16 (0.7) | 13 (0.9) | 3 (0.4) | 0.29 |
| **Race** | 0.74 |
| **White** | 2165 (96.4) | 1456 (96.2) | 709 (96.7) |  |
| **Black** | 54 (2.4) | 39 (2.6) | 15 (2.1) |  |
| **Other** | 27 (1.2) | 18 (1.2) | 9 (1.2) |  |
| **Pelvic Organ Prolapse Quantification Stage** | 0.26 |
| **Stage 1**  | 5 (0.2) | 5 (0.3) | 0 (0) |  |
| **Stage 2** | 536 (23.6) | 361 (23.7) | 175 (23.3) |  |
| **Stage 3** | 1449 (63.8) | 958 (62.9) | 491 (65.5) |  |
| **Stage 4** | 282 (12.4) | 198 (13.0) | 84 (11.2) |  |
| **Past Medical History** |  |
| **Hypertension** | 1275 (55.7) | 862 (56.1) | 413 (55.1) | 0.66 |
| **Diabetes** | 344 (15.0) | 230 (15.0) | 114 (15.2) | 0.88 |
| **Cancer\*** | 478 (20.9) | 307 (20.0) | 171 (22.8) | 0.12 |
| **History of VTE** | 141 (6.2) | 79 (5.1) | 62 (8.3) | **<0.01** |
| **History of stroke** | 40 (1.8) | 20 (1.3) | 20 (2.7) | **0.02** |
| **Chronic anticoagulant use** | 175 (7.7) | 110 (7.2) | 65 (8.7) | 0.21 |
| **Charlson Comorbidity Index** | 3 (2-4) | 3 (2-4) | 3 (2-4) | 0.58 |
| **Caprini Score** | 6 (5-8) | 6 (5-8) | 6 (5-8) | **<0.01** |
|  **Caprini Score 5-6** | 1335 (58.4) | 919 (59.8) | 416 (55.5) | 0.05 |
|  **Caprini Score 7-8** | 647 (28.3) | 449 (29.2) | 198 (26.4) | 0.16 |
|  **Caprini Score 9+** | 306 (13.4) | 170 (11.1) | 136 (18.1) | **<0.01** |
| **Past Surgical History** |  |
| **Prior hysterectomy** | 919 (40.2) | 634 (41.3) | 285 (38.0) | 0.13 |
| **Prior prolapse surgery** | 316 (13.9) | 209 (13.6) | 107 (14.3) | 0.69 |
| **Prior incontinence surgery** | 185 (8.1) | 135 (8.8) | 50 (6.7) | 0.08 |
| **Surgical Approach** |  |
|  **Vaginal** | 1612 (70.5) | 1155 (75.1) | 457 (60.9) | **<0.01** |
|  **Laparoscopic/Robotic** | 670 (29.3) | 379 (24.6) | 291 (38.8) | **<0.01** |
|  **Abdominal** | 6 (0.3) | 4 (0.3) | 2 (0.3) | 1.00 |
| **Prolapse Surgery Type** |  |
|  **Sacrocolpopexy** | 555 (24.3) | 318 (20.7) | 237 (31.6) | **<0.01** |
|  **USLS/SSLF** | 590 (25.8) | 391 (25.4) | 199 (26.5) | 0.57  |
|  **Colpectomy/Colpocleisis** | 721 (31.5) | 498 (32.4) | 223 (29.7) | 0.20 |
|  **Colporrhaphy (Anterior and/or**  **Posterior)** | 408 (17.8) | 314 (20.4) | 94 (12.5) | **<0.01** |
|  **Transvaginal mesh**  | 8 (0.4) | 8 (0.6) | 0 (0) | 0.06 |
| **Other Surgical Characteristics** |  |
| **Concomitant hysterectomy** | 1003 (43.8) | 647 (42.1) | 356 (47.5) | **0.02** |
| **Concomitant incontinence procedure** | 185 (8.1) | 118 (7.8) | 67 (8.9) | 0.30 |
| **General anesthesia** | 1851 (94.7) | 1175 (93.4) | 676 (97.1) | **<0.01** |
| **Surgery duration, minutes** | 134.4 (68.3) | 134.4 (66.8) | 134.4 (71.0) | 0.99 |
| **Estimated blood loss, mL** | 50 (30-100) | 50 (30-100) | 50 (30-100) | **0.048** |
| **Same-day discharge** | 1410 (71.4) | 877 (69.2) | 533 (75.4) | **<0.01** |
| VTE = venous thromboembolism, USLS = uterosacral ligament suspension, SSLF = sacrospinous ligament fixationData are presented as mean (standard deviation), median (interquartile range), or n (%).Missing data: parity (n=2167), current smoker (n=2212), Hispanic ethnicity (n=2200), race (n=2246), Charlson Comorbidity Index (n=2355), pelvic organ prolapse quantification stage (n=2272), prior hysterectomy (n=2285), prior prolapse surgery (n=2282), prior incontinence surgery (n=2281), surgical approach (n=2287), general anesthesia (n=1954), surgery duration (n=1973), estimated blood loss (n=1983), same-day discharge (n=1974).\*Cancer does not include basal cell carcinoma of the skin.Bolded values are significant (p<0.05). |